ESC 365 - Gender differences in transthyretin cardiac amyloidosis

HFA Premium Access

Gender differences in transthyretin cardiac amyloidosis

Session: Myocardial disease - clinical 5

Topic: Clinical

Speaker: Doctor C. Goena Vives (Donostia, ES)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Cristina Goena Vives

Donostia University Hospital, Donostia (Spain)

3 presentations

0 follower

7 more presentations in this session

Design and rationale for MAGNITUDE, a phase 3, randomised, placebo-controlled trial of NTLA-2001, a CRISPR-based gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy

Speaker: Doctor M. Maurer (New York, US)

T-Amylo score for the diagnosis of transthyretin cardiac amyloidosis in patients with acute heart failure.

Speaker: Ms M. Diez (Buenos Aires, AR)

Prevalence, clinical significance and prognosis value of liver stiffness measurement anomalies in transthyretin cardiac amyloidosis

Speaker: Mrs E. Lointier (Toulouse, FR)

Right ventricular to pulmonary artery uncoupling is an early predictor of poor outcome in wild-type transthyretin cardiac amyloidosis

Speaker: Doctor G. Sinigiani (Padova, IT)

Impairment of right ventricular to pulmonary artery coupling is associated with worse survival in cardiac amyloidosis

Speaker: Doctor A. Jakstaite (Hannover, DE)

Access the full session

Myocardial disease - clinical 5

Speakers: Doctor C. Goena Vives, Doctor M. Maurer, Ms M. Diez, Mrs E. Lointier, Doctor G. Sinigiani...

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources